$18.44
-0.39 (-2.07%)
Open$18.60
Previous Close$18.83
Day High$18.78
Day Low$18.10
52W High$20.79
52W Low$3.03
Volume—
Avg Volume2.24M
Market Cap4.31B
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+253.7% upside
Current
$18.44
$18.44
Target
$65.23
$65.23
$47.67
$65.23 avg
$99.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 20.91M | 8.30M | 220.69M |
| Net Income | -376,495,449 | -252,156,044 | 45.13M |
| Profit Margin | -1,800.6% | -3,206.0% | 20.5% |
| EBITDA | -407,408,592 | -289,236,526 | 96.01M |
| Free Cash Flow | — | — | 41.24M |
| Rev Growth | +123.3% | +48.9% | +11.7% |
| Debt/Equity | — | — | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |